Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
Children and adolescents who receive tisagenlecleucel should be closely monitored for CVAEs, particularly during the first week of treatment.
Authors
- Xiaohan Yang (ORCID: https://orcid.org/0000-0001-5207-4210)
- Ganggang Wang (ORCID: https://orcid.org/0000-0001-5388-0847)
- Qi Mei (ORCID: https://orcid.org/0000-0002-9826-5044)
- Yi Li (ORCID: https://orcid.org/0000-0002-2928-1358)
- Yanjun Liu (ORCID: https://orcid.org/0000-0002-0627-928X)
- Lin Su (ORCID: https://orcid.org/0000-0002-2610-8197)
- Wen Gao (ORCID: https://orcid.org/0000-0002-9590-1260)
Institutions
- Shanxi Medical University (CN)
- Fourth People’s Hospital of Jinan (CN)
- Shanxi Academy of Medical Sciences (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1499143
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09